Good post, My. And obviously you are right in your implication: surely something must have happened in many of these areas/indications that would have been mentioned under normal circumstances -- so silence must be ruling. We have also heard rumors that the GBM preclinical study has had exciting findings, and they were not mentioned.

I don't mean to put a damper on your whole post, but it is my understanding that as of July 15th the LATCH trials were not yet underway, and that OHSU was planning a press release when it does launch -- probably before September.

Meanwhile: yes. The silence hasn't helped the share price, but we all believe good things are going on that have not been reported, for the best of reasons.